Browse the evidence

Phentermine/topiramate ER produces the highest placebo-subtracted weight loss (6.8%) among approved anti-obesity drugs, with significant improvements in cardiovascular risk factors.

Phentermine/topiramate is the most effective approved drug for weight loss, helping patients lose nearly 7% more weight than placebo. It also improves blood pressure and lipids. However, it requires strict contraception in women of childbearing age.

Vitamin D3 supplementation (average ~3,000 IU/day) for at least 3 months significantly reduces systolic and diastolic blood pressure, serum parathyroid hormone (PTH), high-sensitivity C-reactive protein (hs-CRP), and total cholesterol, while increasing HDL cholesterol.

If you are considering vitamin D3 for heart health, aim for a daily dose around 3,000 IU, taken consistently for at least 3 months. This approach has been shown in large-scale reviews to modestly lower blood pressure, reduce inflammation, and improve cholesterol profiles. It is not a magic bullet for arterial stiffness, but it is a low-risk strategy to support overall cardiovascular metrics, especially if you have low baseline levels.

Tirzepatide at 15 mg and maximum tolerated dose (MTD) provides superior weight loss efficacy compared to semaglutide (2.4 mg and MTD) in non-diabetic adults with obesity, but this benefit is offset by significantly higher rates of gastrointestinal side effects and treatment discontinuation.

If you are a non-diabetic adult with obesity seeking maximum weight loss, tirzepatide at 15mg or MTD is statistically more effective than semaglutide. However, you must accept a higher risk of gastrointestinal side effects and a higher chance of stopping the medication due to those side effects. Discuss your tolerance for potential side effects versus the desire for maximum weight loss with your provider.

Subcutaneous semaglutide (up to 2.4 mg weekly) produces a mean weight reduction of 11.85% in adults with obesity without diabetes compared to placebo, though it significantly increases the risk of gastrointestinal adverse events and treatment discontinuation.

If you have obesity without diabetes, semaglutide (up to 2.4 mg weekly) can help you lose about 12% of your body weight, which is significantly more than placebo. However, you must be prepared for a high likelihood of temporary stomach issues like nausea or diarrhea. These side effects are common but usually mild and go away. You will also need to follow a reduced-calorie diet and exercise plan alongside the medication for best results.

Semaglutide significantly reduces Major Adverse Cardiovascular Events (MACE) and hospitalization for heart failure (HHF) risk, while Tirzepatide significantly reduces HHF risk, offering cardiovascular protection beyond weight loss.

If you have obesity and cardiovascular disease or heart failure, Semaglutide and Tirzepatide are not just weight loss drugs; they offer proven cardiovascular protection. Semaglutide reduces the risk of major heart events, and Tirzepatide reduces hospitalizations for heart failure. These benefits are independent of, but additive to, the weight loss achieved.

Weight loss triggers compensatory metabolic adaptations (hormonal and energy expenditure changes) that promote weight regain, making long-term maintenance difficult.

Expect that maintaining weight loss will be biologically challenging. Your body will fight back with increased hunger and decreased energy expenditure. This is normal and not your fault. Long-term success requires ongoing strategies to manage these biological drivers, such as regular self-monitoring and possibly higher protein intake to combat hunger hormones.

The weight loss efficacy of Tirzepatide is dose-dependent and increases with longer duration of treatment.

If you are taking Tirzepatide, sticking with the treatment for a longer duration and reaching the higher maintenance doses (like 15mg) will result in more significant weight loss than lower doses. The drug's effectiveness scales with the dose.

Obesity accelerates the loss of pancreatic beta-cell function and insulin sensitivity through ectopic adipose expansion, systemic low-grade inflammation, and lipotoxicity, leading to Type 2 Diabetes Mellitus (T2DM).

Obesity is not just about weight; it actively damages the body's ability to use insulin and produce it via inflammation and fat accumulation in organs like the liver and pancreas. Managing obesity is critical to preventing or delaying T2DM, but it requires addressing metabolic health, not just scale weight.

High consumption of sugar-sweetened beverages (SSBs) causes an increased risk of coronary heart disease (CHD) and type 2 diabetes, independent of body mass index (BMI).

Stop drinking sugar-sweetened beverages. Even if you maintain your weight, the sugar in these drinks independently raises your risk of heart disease and type 2 diabetes. Choose water, unsweetened tea, or coffee instead.

High consumption of glycemic load causes an increased risk of type 2 diabetes.

Reduce your glycemic load by choosing whole, unprocessed foods. High glycemic load foods like white bread and sugary drinks increase the risk of type 2 diabetes. Opt for vegetables, fruits, and whole grains.

Type 2 diabetes should be managed as a component of Metabolic Dysfunction Syndrome (MDS) rather than solely as a hyperglycemic disorder, requiring holistic protection of target organs against all MDS-related metabolic disorders.

Do not treat Type 2 Diabetes as just a 'blood sugar problem.' Your risk of organ damage comes from the combination of high blood sugar, high blood pressure, high lipids, and excess weight. Effective management requires addressing all these metabolic factors together to protect your heart, kidneys, and eyes, rather than focusing on glucose alone.

Higher dietary glycemic index (GI) and glycemic load (GL) are robustly associated with an increased risk of incident type 2 diabetes (T2D) in adults initially in good health.

To lower your risk of type 2 diabetes, prioritize foods with a lower glycemic index and load. This means choosing carbohydrates that digest more slowly, rather than just reducing the total amount of carbs. The evidence suggests that the quality of carbohydrates, specifically their impact on blood sugar rise, is a significant predictor of diabetes risk in healthy adults.

Triple hormone receptor agonist retatrutide (1-12 mg weekly) significantly reduces liver fat in patients with metabolic dysfunction-associated steatotic liver disease (MASLD), achieving near-maximal reduction (~80%) at 24 weeks with high doses (8-12 mg).

For patients with MASLD, high-dose retatrutide (8-12 mg weekly) offers a highly effective treatment to significantly reduce liver fat, often normalizing it within 24 weeks. This hormonal intervention addresses the root metabolic drivers of liver fat accumulation more potently than current GLP-1 mono-agonists.

Higher circulating or adipose tissue levels of the dairy fat biomarkers pentadecanoic acid (15:0), heptadecanoic acid (17:0), and trans-palmitoleic acid (t16:1n-7) are associated with a significantly lower incidence of type 2 diabetes.

High levels of specific fatty acids (15:0, 17:0, and t16:1n-7) in your blood or fat tissue, which serve as biomarkers for dairy fat consumption, are linked to a lower risk of developing type 2 diabetes. This suggests that moderate consumption of dairy products may be metabolically beneficial, contrary to the general advice to avoid all saturated fats.

Tirzepatide, a dual agonist of GLP-1 and GIP receptors, achieves significant body weight and glucose control in patients with obesity and type 2 diabetes.

Tirzepatide, which activates both GLP-1 and GIP receptors, is an effective treatment for obesity and type 2 diabetes, leading to significant improvements in body weight and glucose control. It represents a newer class of therapy with promising clinical results.

Short-term time-restricted feeding (8h window) alters the rhythmicity of serum lipids and muscle amino acids without perturbing core clock gene expression in skeletal muscle.

If you practice time-restricted feeding, expect changes in how your body processes fats and amino acids throughout the day, specifically by increasing the 'peaks' of certain metabolic signals in muscle. This happens even if your body's core biological clock genes remain unchanged. Focus on the timing of nutrient availability rather than trying to 'reset' your biology.

Multi-targeting agonists (tirzepatide and peptide 20) that activate GIPR, GLP-1R, and GCGR provide superior metabolic efficacy compared to GLP-1 mono-agonists (like semaglutide) by leveraging distinct structural binding modes and retaining glucagon receptor function.

For individuals managing Type 2 Diabetes or Obesity, newer multi-targeting therapies (like tirzepatide) that activate multiple metabolic receptors (GIP, GLP-1, and Glucagon) have demonstrated superior weight loss and glucose control compared to older GLP-1-only medications. This suggests that targeting multiple hormonal pathways simultaneously may offer better clinical outcomes than single-pathway treatments.

Higher BMI causally increases the risk of coronary heart disease (CHD), and this effect is significantly mediated by elevated triacylglycerol levels, higher HbA1c, and type 2 diabetes risk.

High body weight increases heart disease risk, but much of that risk comes from how it affects your blood fats (triglycerides) and blood sugar (HbA1c/Diabetes). Managing these specific metabolic markers is crucial for heart health, potentially more so than focusing on LDL cholesterol alone, which this study suggests isn't a primary mediator of BMI's effect.

Bariatric surgery reverses obesity-associated secondary hypogonadism (MOSH) in men, leading to increased total and free testosterone levels and improved sexual function.

If you are a severely obese man with low testosterone, bariatric surgery can naturally restore your hormone levels and sexual function by reversing the obesity that was suppressing your hormones.

Evening exercise training (18:30 hours) improves glycaemic control and reverses high-fat diet-induced metabolic perturbations in overweight/obese men, whereas morning exercise (06:30 hours) does not.

If your goal is optimizing blood sugar control and metabolic health, especially if you consume a high-fat diet, try to schedule your workouts for the evening (around 18:30). Morning exercise still improves your heart and lung fitness, but it may not offer the same metabolic protection against poor diet choices. If you must exercise in the morning, be mindful that it might not counteract the negative metabolic effects of a high-fat diet as effectively as evening training.

Oral semaglutide (7-14 mg/day) provides glucose-lowering and weight-loss effects comparable to subcutaneous formulations, though with lower bioavailability requiring higher doses.

If you prefer pills over injections, oral semaglutide is an option. You must take it on an empty stomach before breakfast, which requires discipline. It uses a higher dose than the shot version to compensate for lower absorption.

Vagal afferent signaling mediates nutrient-specific learning and satiation, and its blunting in obesity contributes to excessive weight gain, while targeted neuromodulation (stimulation or blockade) can reduce food intake and body weight.

Your gut communicates directly with your brain via the vagus nerve to regulate hunger and satiety. In obesity, this signal can become blunted. Therapies that stimulate this nerve (like non-invasive vagus nerve stimulation) or mimic gut hormones (like GLP-1 agonists) can help restore this signaling, reducing food intake and aiding weight loss. Focus on strategies that support gut-brain communication.

Tirzepatide's GIP receptor agonism directly enhances adipocyte glucose uptake and lipid clearance in the fed state by cooperating with insulin, contributing to reduced serum triglycerides without increasing adiposity.

Tirzepatide works partly by helping your fat cells clear sugar and fat from your blood more effectively when you eat, thanks to its GIP receptor activity. This helps lower blood fat levels without making you gain more body fat, complementing the weight loss driven by other mechanisms.

In the fasted state (low insulin), tirzepatide's GIP receptor agonism stimulates lipolysis (fat breakdown) to release stored energy, counter-regulating insulin's storage signal.

When you are not eating, tirzepatide helps your fat cells release stored fat for energy. This happens because the drug's GIP activity stimulates fat breakdown when insulin is low, ensuring your body can access energy stores during fasting periods.